Bezlotoxumab Promising Against Recurrent Clostridium difficile

Share this content:
Bezlotoxumab Promising Against Recurrent <i>Clostridium difficile</i>
Bezlotoxumab Promising Against Recurrent Clostridium difficile

THURSDAY, Jan. 26, 2017 (HealthDay News) -- Bezlotoxumab (Zinplava) is effective in reducing the risk of recurrent Clostridium difficile infection, according to research published in the Jan. 26 issue of the New England Journal of Medicine.

The two trials involved 2,655 adults who all received antibiotics for a first-time or recurrent C. difficile infection. Some patients were randomly assigned to receive a bezlotoxumab infusion, while the rest received a saline infusion that served as a placebo.

The researchers found that over 12 weeks, 16 to 17 percent of bezlotoxumab patients suffered a recurrent infection. That compared with 26 to 28 percent of placebo patients. The drug's main side effects included fever, nausea, and diarrhea -- which affected between 5 and 7 percent of patients. According to Merck, the drug's manufacturer, there is also a concern about worsening heart failure in patients who already have the disease.

Lead researcher Mark Wilcox, M.D., a professor of medical microbiology at the University of Leeds in the United Kingdom, told HealthDay that doctors will have to give the drug based on patients' personal odds of a recurrence. According to Wilcox, some high-risk patients include those who are age 65 or older, have a compromised immune system, or have a severe C. difficile infection. "Bezlotoxumab was more effective in such patients," Wilcox said. "So doctors should consider adding it to standard-of-care antibiotics according to these risk factors."

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which manufactures bezlotoxumab and funded the trials.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »